PET scans reveal hidden clues in breast cancer survival
NCT ID NCT07316439
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study looks at 197 women with advanced breast cancer to compare survival between those whose tumors lost estrogen receptors (ER) and those with triple-negative disease. Researchers used a special PET scan to track receptor changes. The goal is to understand how these changes affect prognosis and guide future treatment decisions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200032, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
18F-fluoroestradiol (FES) PET/CT imaging
What this could lead to
If successful, this could help doctors better predict outcomes for breast cancer patients whose tumors change hormone receptor status.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all breast cancer types or populations.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.